Essex Investment Management Co. LLC Purchases 23,344 Shares of Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN)

Essex Investment Management Co. LLC boosted its position in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) by 12.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned 207,574 shares of the company’s stock after purchasing an additional 23,344 shares during the quarter. Essex Investment Management Co. LLC’s holdings in Day One Biopharmaceuticals were worth $2,630,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of DAWN. R Squared Ltd acquired a new stake in shares of Day One Biopharmaceuticals in the fourth quarter valued at approximately $31,000. Quest Partners LLC grew its position in Day One Biopharmaceuticals by 9,238.6% in the third quarter. Quest Partners LLC now owns 7,751 shares of the company’s stock valued at $108,000 after purchasing an additional 7,668 shares in the last quarter. E Fund Management Co. Ltd. acquired a new stake in Day One Biopharmaceuticals in the 4th quarter valued at $143,000. Dynamic Technology Lab Private Ltd bought a new stake in Day One Biopharmaceuticals during the 3rd quarter worth about $174,000. Finally, XTX Topco Ltd acquired a new position in shares of Day One Biopharmaceuticals during the 3rd quarter worth about $178,000. Institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Price Performance

DAWN opened at $8.67 on Monday. Day One Biopharmaceuticals, Inc. has a fifty-two week low of $8.02 and a fifty-two week high of $18.07. The company’s 50 day moving average price is $11.77 and its two-hundred day moving average price is $13.19. The firm has a market capitalization of $878.75 million, a price-to-earnings ratio of -8.42 and a beta of -1.38.

Day One Biopharmaceuticals (NASDAQ:DAWN) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.34). The company had revenue of $29.21 million during the quarter, compared to the consensus estimate of $27.11 million. As a group, equities research analysts predict that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current year.

Analyst Upgrades and Downgrades

Several research analysts have weighed in on the company. HC Wainwright lowered their price target on Day One Biopharmaceuticals from $40.00 to $36.00 and set a “buy” rating on the stock in a research report on Wednesday, February 26th. Wedbush reaffirmed an “outperform” rating and set a $32.00 price target on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. Needham & Company LLC reissued a “buy” rating and issued a $32.00 price objective on shares of Day One Biopharmaceuticals in a research report on Wednesday, February 26th. JPMorgan Chase & Co. dropped their target price on shares of Day One Biopharmaceuticals from $39.00 to $34.00 and set an “overweight” rating on the stock in a report on Wednesday, March 5th. Finally, The Goldman Sachs Group reduced their price target on Day One Biopharmaceuticals from $48.00 to $43.00 and set a “buy” rating for the company in a report on Monday, February 10th. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, Day One Biopharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $34.57.

Insider Buying and Selling at Day One Biopharmaceuticals

In other Day One Biopharmaceuticals news, insider Samuel C. Blackman sold 30,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $13.31, for a total transaction of $399,300.00. Following the transaction, the insider now owns 1,034,015 shares in the company, valued at approximately $13,762,739.65. This represents a 2.82 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, General Counsel Adam Dubow sold 4,646 shares of the company’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $11.96, for a total transaction of $55,566.16. Following the completion of the sale, the general counsel now owns 39,602 shares in the company, valued at $473,639.92. This represents a 10.50 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders have sold 51,064 shares of company stock valued at $651,225. 8.40% of the stock is currently owned by company insiders.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma.